Abraxis BioScience, Inc. Initiates Patient Enrollment in Phase II Study of Coroxane(TM) for Prevention of Restenosis in Peripheral Vascular Disease
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII - News), a fully integrated biotechnology company, today announced it has initiated enrollment in its Phase II clinical trial to evaluate the efficacy and safety of Coroxane™ for the prevention and reduction of restenosis following revascularization of the superficial femoral artery (SFA).